Orally administered isoflavones are present as glucuronides in the human prostate

Nutrition and Cancer

Volumn 60, Issue 4, 2008, Pages 461-468

  Guy, Laurent ^a   Védrine, Nicolas ^a   Urpi Sarda, Mireia ^b   Gil Izquierdo, Angel ^b   Al Maharik, Nawaf ^c   Boiteux, Jean Paul ^a   Scalbert, Augustin ^b   Rémésy, Christian ^b   Botting, Nigel P ^c   Manach, Claudine ^b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b INRA and University of Auvergne   (France)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYCONE; DAIDZEIN; DAIDZEIN DIGLUCURONIDE; DAIDZEIN DISULFATE; DAIDZEIN GLUCURONIDE; DAIDZEIN SULFATE; DAIDZEIN SULFOGLUCURONIDE; DIHYDRODAIDZEIN GLUCURONIDE; DIHYDROGENISTEIN GLUCURONIDE; DIHYDROGLYCITEIN GLUCURONIDE; EQUOL; EQUOL DIGLUCURONIDE; EQUOL DISULFATE; EQUOL GLUCURONIDE; EQUOL SULFATE; EQUOL SULFOGLUCURONIDE; EVESTREL; GENISTEIN; GENISTEIN DIGLUCURONIDE; GENISTEIN DISULFATE; GENISTEIN GLUCURONIDE; GENISTEIN SULFATE; GENISTEIN SULFOGLUCURONIDE; GLUCURONIDE; GLYCITEIN; GLYCITEIN DIGLUCURONIDE; GLYCITEIN DISULFATE; GLYCITEIN SULFATE; GLYCITEIN SULFOGLUCURONIDE; ISOFLAVONE DERIVATIVE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; PREOPERATIVE PERIOD; PROSTATE HYPERTROPHY; SOYBEAN; TANDEM MASS SPECTROMETRY;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET; DIETARY SUPPLEMENTS; GENISTEIN; GLUCURONIDES; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 46349093383     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580801911761     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57, 43-66, 2007.
2. Hill C and Doyon F: The frequency of cancer in France in year 2002, and trends since 1968. Bull Cancer 93, 7-11, 2006.
3. Messina MJ: Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 61, 117-131, 2003.
4. Hsing AW, Tsao L, and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85, 60-67, 2000.
5. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, et al.: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63, 963-966, 1991.
6. Cook LS, Goldoft M, Schwartz SM, and Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 161, 152-155, 1999.
7. Sim HG and Cheng CWS: Changing demography of prostate cancer in Asia. Eur J Cancer 41, 834-845, 2005.
8. Yan L and Spitznagel EL: Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 117, 667-669, 2005.
9. Pollard M and Suckow MA: Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model. Comp Med 56, 461-467, 2006.
10. Magee PJ and Rowland IR: Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91, 513-531, 2004.
11. Hempstock J, Kavanagh JP, and George NJR: Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br J Urol 82, 560-563, 1998.
12. Messina M, Kucuk O, and Lampe JW: An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 89, 1121-1134, 2006.
13. Bemis DL, Katz AE, and Buttyan R: Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 15, 1191-1200, 2006.
14. Morrissey C and Watson RW: Phytoestrogens and prostate cancer. Curr Drug Targets 4, 231-241, 2003.
15. Sarkar FH and Li Y: The role of isoflavones in cancer chemoprevention. Front Biosci 9, 2714-2724, 2004.
16. Al-Maharik N and Botting NP: A facile synthesis of isoflavone 7-O-glucuronides. Tetrahedron Lett 47, 8703-8706, 2006.
17. Messina M, Nagata C, and Wu AH: Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55, 1-12, 2006.
18. Manach C, Williamson G, Morand C, Scalbert A, and Remesy C: Bioavailability and bioefficacy of polyphenols in humans: I. review of 97 bioavailability studies. Am J Clin Nutr 81, 230S-242S, 2005.
19. Morton MS, Chan PS, Cheng C, Blacklock N, Matos-Ferreira A, et al.: Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 32, 122-128, 1997.
20. Hong SJ, Kim SI, Kwon SM, Lee JR, and Chung BC: Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 43, 236-241, 2002.
21. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, et al.: Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 135, 1400-1406, 2005.
22. Rannikko A, Petas A, Rannikko S, and Adlercreutz H: Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestrogen supplementation. Prostate 66, 82-87, 2006.
23. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, et al.: Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131, 1362S-1375S, 2001.
24. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, et al.: Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 75, 126-136, 2002.
25. Zhang Y, Hendrich S, and Murphy PA: Glucuronides are themain isoflavone metabolites in women. J Nutr 133, 399-404, 2003.
26. Levsen K, Schiebel HM, Behnke B, Dotzer R, Dreher W, et al.: Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. J Chromatogr A 1067, 55-72, 2005.
27. de Graaf M, Boven E, Scheeren HW, Haisma HJ, and Pinedo HM: Beta-glucuronidase-mediated drug release. Curr Pharm Des 8, 1391-1403, 2002.
28. Zhang Y, Song TT, Cunnick JE, Murphy PA, and Hendrich S: Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr 129, 399-405, 1999.
29. Turner R, Baron T, Wolffram S, Minihane AM, Cassidy A, et al.: Effect of circulating forms of soy isoflavones on the oxidation of low density lipoprotein. Free Radic Res 38, 209-216, 2004.
30. Rimbach G, Weinberg PD, de Pascual-Teresa S, Alonso MG, Ewins BA, et al.: Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim Biophys Acta 1670, 229-237, 2004.
31. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, et al.: Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77, 875-882, 2003.